Practical applications of a new botulinum toxin

Area of Science:

• Cosmetic Dermatology
• Neurology
• Pharmacology

Background:

• Clostridium botulinum type A neurotoxins are widely used for cosmetic procedures globally.
• The FDA approved abobotulinumtoxinA (Dysport) in 2009, expanding treatment options.
• The introduction of Dysport necessitates a comparison with onabotulinumtoxinA (Botox).

Purpose of the Study:

• To compare the similarities and differences between Botox and Dysport.
• To provide practical guidelines for using Dysport.
• To address common questions regarding neurotoxin use and future market developments.

Main Methods:

• Review of clinical experience with Botox and Dysport.
• Analysis of peer-reviewed, published clinical trials.
• Comparison of product characteristics, unit conversions, injection techniques, adverse events, and duration of effect.

Main Results:

• Botox and Dysport can be used for similar on- and off-label cosmetic applications.
• Understanding product-specific differences is crucial for optimal outcomes and minimizing side effects.
• Guidelines for judicious use of both neurotoxins are provided.

Conclusions:

• Both onabotulinumtoxinA and abobotulinumtoxinA offer valuable therapeutic alternatives.
• Effective use of either neurotoxin requires knowledge of their distinct properties.
• Future market introductions of other neurotoxins are anticipated.